Drug discovery firm Evotec, owner of the API manufacturer Aptuit, is a member of the Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration, which was launched formally on 27 February. This will aim to transform global action on TB, which causes more deaths than any other infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018.